نتایج جستجو برای: primary and metastatic melanoma

تعداد نتایج: 16947239  

2006
Lyn M. Duncan Jim Deeds John Hunter Jing Shao Lisa M. Holmgren Elizabeth A. Woolf Robert I. Tepper Andrew W. Shyjan

We have used differential cDNA display to search for genes whose expression correlates with an aggressive phenotype in variants of the B16 murine melanoma line, B16-F1 and 1516-1 10. This analysis identified a novel gene, termed melastatin, that is expressed at high levels in poorly metastatic variants of B16 melanoma and at much reduced levels in highly metastatic B16 variants. Melastatin was ...

Journal: :Cancer research 1998
L M Duncan J Deeds J Hunter J Shao L M Holmgren E A Woolf R I Tepper A W Shyjan

We have used differential cDNA display to search for genes whose expression correlates with an aggressive phenotype in variants of the B16 murine melanoma line, B16-F1 and B16-F10. This analysis identified a novel gene, termed melastatin, that is expressed at high levels in poorly metastatic variants of B16 melanoma and at much reduced levels in highly metastatic B16 variants. Melastatin was al...

Journal: :Cancer research 2001
D Polsky B C Bastian C Hazan K Melzer J Pack A Houghton K Busam C Cordon-Cardo I Osman

We investigated the role of alterations of HDM2, the human homologue of murine mdm2, in the tumorigenesis and progression of cutaneous melanoma. A well-characterized cohort of 172 cases representing different points in the spectrum of melanocyte transformation (16 dysplastic nevi, 11 melanomas in situ, 107 invasive primaries, and 38 metastatic lesions), as well as 11 human melanoma cell lines w...

2015
Kalijn Bol Thomas van den Bosch Gerty Schreibelt Cornelis Punt Carl Figdor Dion Paridaens Jolanda de Vries

Background The presence of monosomy 3 in the primary tumor is widely accepted as the most reliable prognostic parameter, identified in approximately 50% of patients with primary uveal melanoma [1]. Long term studies have shown a 3-year survival rate of 40% if monosomy 3 is present, whereas tumors with normal chromosome 3 status rarely give rise to metastatic disease and have a 90% 3-year surviv...

Journal: :Molecular cancer therapeutics 2003
Eric A Collisson Celina Kleer Mei Wu Abhijit De Sanjiv S Gambhir Sofia D Merajver Michael S Kolodney

Melanoma is a deadly cancer due to its propensity to metastasize. Pharmacological inhibition of cell motility may benefit patients with cutaneous melanoma by preventing metastasis to internal organs. The Rho GTPases are signaling molecules that drive metastasis by controlling cell motility. We found RhoC to be expressed in clinical melanoma specimens and hypothesized that inhibiting its activat...

2012
Camila Ferreira de Souza Patrícia Xander Ana Carolina Monteiro Amanda Gonçalves dos Santos Silva Débora Castanheira Pereira da Silva Sabine Mai Viviane Bernardo José Daniel Lopes Miriam Galvonas Jasiulionis

BACKGROUND Metastatic melanoma is a highly aggressive skin cancer and currently resistant to systemic therapy. Melanomas may involve genetic, epigenetic and metabolic abnormalities. Evidence is emerging that epigenetic changes might play a significant role in tumor cell plasticity and metastatic phenotype of melanoma cells. PRINCIPAL FINDINGS In this study, we developed a systematic approach ...

Journal: :PLoS ONE 2009
Sharon K. Huang Marlene M. Darfler Michael B. Nicholl Jinsam You Kerry G. Bemis Tony J. Tegeler Mu Wang Jean-Pierre Wery Kelly K. Chong Linhda Nguyen Richard A. Scolyer Dave S. B. Hoon

BACKGROUND Melanoma metastasis status is highly associated with the overall survival of patients; yet, little is known about proteomic changes during melanoma tumor progression. To better understand the changes in protein expression involved in melanoma progression and metastasis, and to identify potential biomarkers, we conducted a global quantitative proteomic analysis on archival metastatic ...

2011
Darko Katalinic Branimir Anic Ranka Stern-Padovan Miroslav Mayer Mirna Sentic Nada Cikes Kamelija Zarkovic Snjezana Dotlic Stjepko Plestina

Primary spinal melanomas are extremely rare lesions. In 1906, Hirschberg reported the first primary spinal melanoma, and since then only 40 new cases have been reported. A 47-year-old man was admitted suffering from low back pain, fatigue and loss of body weight persisting for three months. He had a 17-year-old history of an operated primary spinal melanoma from T7-T9, which had remained stable...

Journal: :thrita 0
amirpasha ebrahimi department of surgery, hepatobiliary and liver transplantation division, imam-khomeini hospital, tehran university of medical sciences, tehran, ir iran afshin abdi rad department of surgical pathology, cancer institute, imam-khomeini hospital, tehran university of medical sciences, tehran, ir iran massoome najafi department of surgery, cancer institute, imam-khomeini hospital, tehran university of medical sciences, tehran, ir iran; department of surgical pathology, cancer institute, imam-khomeini hospital, tehran university of medical sciences, tehran, ir iran. tel/fax: +98-2166581657

introduction primary malignant esophageal melanoma makes up 0.1% to 0.2% of all esophageal malignancies. most physicians assume malignant melanoma as a skin originated neoplasm, however this type of melanoma can occur anywhere in the gastrointestinal tract especially in the esophagus. thus, it is essential to consider malignant melanoma in differential diagnosis of any esophagus masses. case pr...

2012
Bożena Cybulska-Stopa Marta Skoczek Marek Ziobro Tomasz Świtaj Sławomir Falkowski Tadeusz Morysiński Marcin Hetnał Ida Cedrych Piotr Rutkowski

AIM OF THE STUDY The incidence of melanoma is increasing rapidly worldwide. Metastatic melanoma is still an incurable disease, although an era of new drugs is approaching. Current methods to predict outcomes in patients with advanced, metastatic melanoma are limited. A retrospective analysis of a contemporary large group of advanced melanomas was performed to determine clinical prognostic facto...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید